Page 3 - Benjamin Ebert News Today : Breaking News, Live Updates & Top Stories | Vimarsana

San Diego biotech Neomorph, which is developing a protein degradation-based platform to enable novel drug development for hard-to-treat diseases, has raised $109 million in a Series A round of venture capital funding. The startup, launched early this year with seed money from Deerfield Management Co., has opened a research facility in Sorrento Mesa. Deerfield also provided this latest Series A funding. The investment firm has a longstanding partnership with the Dana-Farber Cancer Institute in Cambridge, Mass. Neomorph is expected to collaborate with the Center for Protein Degradation at Dana-...

Neomorph, Inc., a San Diego, CA-based biotechnology company, raised $109m in Series A financing. The company intends to use the funds to further develop its platform, advance lead programs, and expand the research team. Deerfield Management Company established Neomorph earlier this year with scientific founders Phil Chamberlain, DPhil; Eric Fischer, PhD; Benjamin Ebert, MD, PhD; and Scott Armstrong, MD, PhD. The company is building a protein degradation entity, focused on “molecular glue” degraders. Targeted protein degradation offers opportunities to develop novel therapeutics across a...

socaltech.com San Diego-based Neomorph, a biotech startup focused on protein degradation, said today that it has raised $109M in a Series A funding. The funding came from Deerfield Management. The company said its targeted protein degradation technology is aimed at developing novel therapeutics across a broad range of disease areas, including oncology. The company's scientific founders are Phil Chamberlain, DPhil; Eric Fischer, PhD; Benjamin Ebert, MD, PhD; and Scott Armstrong, MD, PhD. The company said it will use the Series A funding to further develop its platform, advance lead programs, ...